STANFORD, Calif. — A widely-available anti-inflammatory prescription drug can reduce the risk of a common skin cancer in humans, according to a researcher at Stanford's School of Medicine. Although oral administration of the drug, celecoxib, is associated with an increased risk of heart attack and stroke in some people, it's possible that topical application could have a safer, protective effect for people prone to developing the cancers, called basal cell carcinomas, the researcher believes. "Basal cell carcinomas are the most common human cancer in the United States," said Jean Tang, MD, PhD, assistant professor of dermatology, "and their incidence is...